An interventional study of RF Ablation in Atrial Flutter Typical, sponsored by Imricor Medical Systems. Recruiting at 6 sites in 4 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-20.
Sponsored by Imricor Medical Systems · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 80 studies in Atrial Flutter with a site in United States — 11 open to participants now, 14 under way, 1 of them phase 3. Atrial Flutter · United States.
Among the 80 studies in Atrial Flutter with a site in United States, this one is the 39th largest by planned enrollment of the 55 interventional ones that give a count, is one of 7 that started in 2024, is one of 28 with no phase, reaches primary completion later than 5 of the 13 other live ones, and was the 68th registered.
223 studies on the registry are indexed under Atrial Flutter; 51 are open to participants now.
Browse Atrial Flutter studies →11 of the 80 studies in Atrial Flutter with a site in United States are open now. Recruiting first, the newest first:
Wake Forest University Health Sciences · Sites in United States
Ages 18+
HeartBeam, Inc. · Sites in United States
Ages 18+ · Healthy volunteers
Wake Forest University Health Sciences · Sites in United States
Ages 18+
Ottawa Heart Institute Research Corporation · Sites in United States, Canada
Ages 18+
Population Health Research Institute · Sites in United States, Austria, Canada and 2 more countries
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 35 Atrial Flutter studies recruiting now, 29 (83%) set no upper age limit and none (0%) stop at 75 or younger; 1 takes children under 18; 4 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
80 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 6 · Phase 3 19 · Phase 4 8
First in 2001; this study’s year is marked. 7 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 91 is below the median of 150 across 155 interventional studies indexed under Atrial Flutter.
Median enrollment 196 across the 55 interventional studies, 126 across the 22 observational. Of the 63 that completed or were terminated, 30 (48%) have results posted.
This tab as a report to print or save as PDF → With an account.
38 of 80 have an industry lead sponsor. The 10 most frequent:
Imricor Medical Systems is the lead sponsor of 2 studies on the registry; 2 are open to participants now.
Imricor Medical Systems has 1 study filed under Atrial Flutter — fewer than ten, so there is no comparison to draw.
6 of the studies in Atrial Flutter with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05997914University of Massachusetts, WorcesterStorytelling for Reducing Gap in Anticoagulation Use in African Americans With Atrial Fibrillation | 2026-11 |
| NCT05014802Tulane UniversityBaseline Atrial Fibrosis Predicts Risk for Post-operative Atrial Fibrillation in Patients Undergoing Cardiac Surgery | 2026-12 |
| NCT06876896Wake Forest University Health SciencesIntra-abdominal Pressure (IAP) During PFA Treatment of A-fib/ A-Flutter | 2026-12-30 |
| NCT05904548Imricor Medical SystemsAtrial Flutter Ablation in the iCMR | 2026-12-31 |
| NCT06735534Boston Scientific CorporationRepeat Ablation of Persistent Atrial Fibrillation, Including Mitral Isthmus Catheter Ablation, With the FARAPULSE Pulsed Field Ablation System | 2027-04 |
Add all 6 to your calendar (.ics) → With an account.
Among the 80 studies in Atrial Flutter with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The VISABL-AFL clinical investigation is a prospective, single-arm, multi-center, interventional, Investigational Device Exemption (IDE) trial. The primary objectives of VISABL-AFL are to assess the safety and efficacy of radiofrequency (RF) ablation of type-I atrial flutter performed with the Vision-MR Ablation Catheter 2.0 in the iCMR environment.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Type 1 Atrial Flutter ablation performed in the iCMR with the Vision-MR Ablation Catheter 2.0 and associated Advantage-MR EP recorder and stimulator system.
Device: RF Ablation
RF ablation for type I atrial flutter under iCMR guidance
Primary Efficacy Endpoint: Bi-directional block confirmation
Confirmation of bidirectional conduction block of the CTI with the Vision-MR Ablation Catheter 2.0 and Osypka HAT 500 RF generator \& irrigation pump.
Time frame: Time of procedure, following delivery of last ablation energy delivery point
Primary Safety Endpoint: Composite of serious cardiovascular adverse events
A composite of the following serious adverse events as adjudicated by an independent clinical events committee: * Cardiac perforation/tamponade * Cerebrovascular accident (CVA) * Transient ischemic attack (TIA) * Complete heart block * Myocardial infarction * Pulmonary embolism * MR-related serious adverse events * Unanticipated device related serious adverse events * Death
Time frame: 7-days post procedure
Chronic Efficacy Endpoint: Freedom from type 1 atrial flutter at 90 days
The percent of subjects free of documented type I atrial flutter recurrence
Time frame: 3 months (90 days)
Chronic Safety Endpoint: all serious adverse event rate for duration of study
Rate of Serious Adverse Events during the clinical investigation as adjudicated by an independent clinical events committee
Time frame: 3 months (90 days)
Not enrolling at this site.
Started Jun 2024 (actual). Primary completion is estimated for Dec 2026, 30 months after the start.
Of 55 interventional studies with no phase under Atrial Flutter, half reached primary completion within 31 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 63. This study's planned 30 months is close to that.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Imricor Medical Systems